Table 2.
Airway inflammation in levofloxacin and placebo groups over time series
| Treatment | Baseline | Day 7 | Day 14 | Day 28 |
|---|---|---|---|---|
| Total sputum cell count (×106/g) | ||||
| Placebo | 2.1 (1.3–3.2) | 1.6 (0.9–3.0) | 1.7 (1.0–3.1) | 2.4 (1.5–3.8) |
| Levofloxacin | 3.0 (1.8–4.8) | 2.1 (1.1–3.9) | 2.2 (0.9–5.5) | 3.0 (1.7–5.2) |
| Neutrophil count (%)* | ||||
| Placebo | 66.2 (19.8) | 64.9 (17.7) | 58.7 (20.9) | 59.1 (19.4) |
| Levofloxacin | 70.4 (21.4) | 58.2 (16.7) | 68.9 (16.4) | 70.1 (15.6) |
| Total neutrophil count (×106/g) | ||||
| Placebo | 1.3 (0.8–2.2) | 1.0 (0.5–2.1) | 1.0 (0.5–1.9) | 1.3 (0.7–2.4) |
| Levofloxacin | 2.1 (1.1–4.0) | 1.0 (0.4–2.6) | 1.3 (0.4–3.8) | 1.7 (0.9–3.1) |
| Interleukin-8 (ng/mL) | ||||
| Placebo | 81.9 (45.5) | 113.6 (82.3) | 120.8 (62.1) | 95.4 (75.0) |
| Levofloxacin | 95.1 (67.7) | 85.0 (56.3) | 124.8 (69.7) | 91.7 (74.5) |
| Log bacterial load (cfu/mL−1)† | ||||
| Placebo | 6.05 (0.2) | 6.18 (0.3) | 6.28 (0.3) | 6.15 (0.3) |
| Levofloxacin | 5.87 (0.2) | 5.33 (0.2) | 5.86 (0.1) | 5.69 (0.2) |
Notes: Data are presented as geometric mean (95% confidence interval) unless stated.
*
Mean (standard deviation)
†
geometric mean (standard deviation).